Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy

Rizzardi, G. Paolo; Harari, Alexandre; Capiluppi, Brunella; Tambussi, Giuseppe; Ellefsen, Kim; Ciuffreda, Donatella; Champagne, Patrick; Bart, Pierre-Alexandre; Chave, Jean-Philippe; Lazzarin, Adriano; Pantaleo, Giuseppe
March 2002
Journal of Clinical Investigation;3/1/2002, Vol. 109 Issue 5, p681
Academic Journal
journal article
Primary HIV-1 infection causes extensive immune activation, during which CD4(+) T cell activation supports massive HIV-1 production. We tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection. Nine adults with primary HIV-1 infection were treated with CsA along with HAART. At week 8, all patients discontinued CsA but maintained HAART. Viral replication was suppressed to a comparable extent in the CsA + HAART cohort and in 29 control patients whose primary infection was treated with HAART alone. CsA restored normal CD4(+) T cell levels, both in terms of percentage and absolute numbers. The increase in CD4(+) T cells was apparent within a week and persisted throughout the study period. CsA was not detrimental to virus-specific CD8(+) or CD4(+) T cell responses. At week 48, the proportion of IFN-gamma-secreting CD4(+) and CD4(+)CCR7(-) T cells was significantly higher in the CsA + HAART cohort than in the HAART-alone cohort. In conclusion, rapid shutdown of T cell activation in the early phases of primary HIV-1 infection can have long-term beneficial effects and establish a more favorable immunologic set-point. Appropriate, immune-based therapeutic interventions may represent a valuable complement to HAART for treating HIV infection.


Related Articles

  • The Cervicovaginal Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and HIV-Uninfected Women. Reimers, Laura L.; Mehta, Supriya D.; Massad, L. Stewart; Burk, Robert D.; Xianhong Xie; Ravel, Jacques; Cohen, Mardge H.; Palefsky, Joel M.; Weber, Kathleen M.; Xiaonan Xue; Anastos, Kathryn; Minkoff, Howard; Atrio, Jessica; D'Souza, Gypsyamber; Qian Ye; Colie, Christine; Zolnik, Christine P.; Spear, Gregory T.; Strickler, Howard D.; Xie, Xianhong // Journal of Infectious Diseases;11/1/2016, Vol. 214 Issue 9, p1361 

    Background:  Bacterial vaginosis (BV) is characterized by low abundance of Lactobacillus species, high pH, and immune cell infiltration and has been associated with an increased risk of human papillomavirus (HPV) infection. We molecularly assessed the cervicovaginal microbiota...

  • Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. Schomaker, Michael; Leroy, Valeriane; Wolfs, Tom; Technau, Karl-Günter; Renner, Lorna; Judd, Ali; Sawry, Shobna; Amorissani-Folquet, Madeleine; Noguera-Julian, Antoni; Tanser, Frank; Eboua, François; Navarro, Maria Luisa; Chimbetete, Cleophas; Amani-Bosse, Clarisse; Warszawski, Josiane; Phiri, Sam; N'Gbeche, Sylvie; Cox, Vivian; Koueta, Fla; Giddy, Janet // International Journal of Epidemiology;Apr2017, Vol. 46 Issue 2, p453 

    Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents.Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients, aged 1-16 years at enrolment, from 19 cohorts in...

  • Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Vergis, Emanuel N.; Paterson, David L.; Wagener, Marilyn M.; Swindells, Susan; Singh, Nina; Vergis, E N; Paterson, D L; Wagener, M M; Swindells, S; Singh, N // International Journal of STD & AIDS;Jul2001, Vol. 12 Issue 7, p463 

    Metabolic complications are being increasingly recognized among HIV-infected patients treated with potent combination antiretroviral therapies. We sought to assess the association of dyslipidaemia with adherence to protease inhibitor (PI) therapy and with the markers of clinical response to...

  • Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. Skurnick, Joan H.; Palumbo, Paul; DeVico, Anthony; Shacklett, Barbara L.; Valentine, Fred T.; Merges, Michael; Kamin-Lewis, Roberta; Mestecky, Jiri; Denny, Thomas; Lewis, George K.; Lloyd, Joan; Praschunus, Robert; Baker, Amanda; Nixon, Douglas F.; Stranford, Sharon; Gallo, Robert; Vermund, Sten H.; Louria, Donald B. // Journal of Infectious Diseases;2/15/2002, Vol. 185 Issue 4, p428 

    Seventeen women who were persistently uninfected by human immunodeficiency virus type 1 (HIV-1), despite repeated sexual exposure, and 12 of their HIV-positive male partners were studied for antiviral correlates of non-transmission. Thirteen women had > or = 1 immune response in the form of CD8...

  • Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses. Uprety, Priyanka; Lindsey, Jane C.; Levin, Myron J.; Rainwater-Lovett, Kaitlin; Ziemniak, Carrie; Bwakura-Dangarembizix, Mutsa; Kaplan, Susan S.; Nelson, Micki; Zadzilka, Amanda; Weinberg, Adriana; Persaud, Deborah // Journal of Infectious Diseases;3/15/2017, Vol. 215 Issue 6, p928 

    Biomarkers of inflammation and immune activation were correlated with rotavirus vaccine responses in 68 human immunodeficiency virus type 1 (HIV-1)–infected (and 116 HIV-exposed but uninfected (HEU) African infants receiving pentavalent rotavirus vaccine (RV5) in a clinical trial....

  • Interleukin 2 treatment for HIV infection. Blankson, Joel; Siliciano, Robert F.; Blankson, J; Siliciano, R F // JAMA: Journal of the American Medical Association;7/12/2000, Vol. 284 Issue 2, p236 

    Editorial. Discusses the disadvantages associated with the use of highly active antiretroviral therapy (HAART) for the treatment of HIV. Challenges to the patient; Complexity and toxicity of the regimen; Rationale for the use of interleukin-2 in HIV-1 infection; Mention of two articles in this...

  • Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality. Seal, Paula; Jackson, David; Chamot, Eric; Willig, James; Nevin, Christa; Allison, Jeroan; Raper, James; Kempf, Mirjam; Schumacher, Joseph; Saag, Michael; Mugavero, Michael; Seal, Paula S; Jackson, David A; Willig, James H; Nevin, Christa R; Allison, Jeroan J; Raper, James L; Kempf, Mirjam C; Schumacher, Joseph E; Saag, Michael S // JGIM: Journal of General Internal Medicine;Jul2011, Vol. 26 Issue 7, p745 

    Background: Many newly diagnosed patients present to outpatient care with advanced HIV infection. More timely HIV diagnosis and initiation of care has the potential to improve individual health outcomes and has public health implications.Objective: To assess temporal...

  • HIV treatment outcomes among people who inject drugs in Victoria, Australia. Walsh, Nick; Mijch, Anne; Watson, Kerrie; Wand, Handan; Fairley, Kit; McNeil, John; Crofts, Nick; Maher, Lisa // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p919 

    Background People who inject drugs (PWID) are a key population affected by HIV. We assessed the effectiveness of HIV treatment among a clinical cohort of people living with HIV (PLHIV) diagnosed and referred for community-based antiretroviral therapy (ART) in Victoria, Australia. Methods HIV...

  • Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. Curran, Adrian; Monteiro, Polyana; Domingo, Pere; Villar, Judit; Imaz, Arkaitz; Martínez, Esteban; Fernández, Irene; Knobel, Hernando; Podzamczer, Daniel; Iribarren, Jose Antonio; Peñaranda, María; Crespo, Manuel // Journal of Antimicrobial Chemotherapy (JAC);May2014, Vol. 69 Issue 5, p1390 

    Objectives Ritonavir-boosted protease inhibitor monotherapy (PIMT) is a maintenance strategy that prevents nucleoside reverse transcriptase inhibitor toxicity and reduces costs. Some trials compare PIMT with combined antiretroviral therapy, but restricted selection criteria and low sample size...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics